Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland

Reuters

05-28

<a href="https://laohu8.com/S/CERS">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland

Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538547682"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538547682\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538547682?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538547682","market":"us","top_or_hot":-1,"title":"Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CERS\">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-28 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CERS\">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLbMK5dw:1","article_id":"2538547682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538547682","pubTimestamp":1748435460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety  and the Swiss Agency for Therapeutic Products  have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","CERS":"Cerus Corporation"},"translate_title":"Cerus Corporation的INT200设备在法国和瑞士获得监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERS":0.9},"content_text":"Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland\n    \n\n        Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}